Physician profile
Devang C Patel
NPI 1457345803
$5,876.36
in general payments reported to CMS, 2019-2025
31 companies · $2,235 in 2025
The $2,235 reported for 2025 was more than what 91% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $637 · 2020: $583 · 2021: $557 · 2022: $1,065 · 2023: $332 · 2024: $467 · 2025: $2,235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,737 · Travel and Lodging: $1,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,737.46 |
| Travel and Lodging | $1,296.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Treace Medical Concepts, INC. | $2,220.28 | 2022-2025 | |
| Smith+Nephew, INC. | $638.54 | 2019-2025 | Stravix, Grafix Pl, Q-Fix |
| Organogenesis INC. | $544.73 | 2020-2025 | Affinity, Via Matrix, Puraply |
| Stryker Corporation | $457.23 | 2019-2025 | Ortholoc 3di, Actishield, Augment Injectable |
| Paratek Pharmaceuticals, INC. | $269.39 | 2021-2025 | Nuzyra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $196.18 | 2019-2024 | Jublia, Cabtreo |
| Melinta Therapeutics, LLC | $182.32 | 2019 | |
| Bioventus LLC | $171.21 | 2020-2025 | Exogen Ultrasound Bone Healing System |
| Osiris Therapeutics INC. | $134.08 | 2019 | |
| Sebela Pharmaceuticals INC. | $130.44 | 2019-2023 | Naftin |
| Wright Medical Technology, INC. | $113.54 | 2019-2020 | |
| Acera Surgical, INC. | $105.52 | 2022 | |
| Grt US Holding, INC. | $96.92 | 2020-2022 | |
| Kerecis Limited | $87.00 | 2019-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Nabriva Therapeutics, Plc | $85.82 | 2020-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $52.59 | 2019 | |
| Heron Therapeutics, INC. | $48.93 | 2021 | |
| Integra Lifesciences Corporation | $46.72 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Dynasplint Systems INC. | $34.64 | 2025 | Dynasplint |
| Next Science LLC | $33.23 | 2023 | Xperience, Surgx, Blastx |
| Solventum Corporation | $31.95 | 2025 | Activ.A.C., Promogran Prisma, V.A.C. Dermatac |
| Ebi, LLC | $28.27 | 2025 | Biomet Ebi Bone Healing System, Biomet Orthopak Non-Invasive Bone Growth Stimulator System |
| Orthofix Medical, INC. | $26.22 | 2024 | Physio-Stim |
| Medshape, INC. | $24.12 | 2023 | Dynanail Helix, Washer, 15 Mm |
| Axogen | $19.38 | 2020 | |
| Fidia Pharma USA INC. | $19.12 | 2019 | |
| Averitas Pharma INC. | $18.16 | 2023 | Qutenza |
| Tactile Systems Technology INC | $17.43 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $17.43 | 2022 | |
| Medtronic, INC. | $14.45 | 2021 | |
| Arthrosurface Incorporated | $10.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devang Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.